



US011213499B1

(12) **United States Patent**
Kunwar et al.

(10) **Patent No.:** **US 11,213,499 B1**
(45) **Date of Patent:** **Jan. 4, 2022**

(54) **USE OF 3,3'-DISELENODIPROPIONIC ACID (DSEPA) AS AN ANTICANCER AGENT**

(71) Applicant: **Secretary, Department of Atomic Energy, Mumbai (IN)**

(72) Inventors: **Amit Kunwar, Mumbai (IN); Vishwa Vipulkumar Gandhi, Mumbai (IN); Khushboo Atulkumar Gandhi, Mumbai (IN); Vikram Suryaprakash Gota, Mumbai (IN); Jayant Sastri Goda, Mumbai (IN); Jyoti Anand Kode, Mumbai (IN); Liladhar Baburao Kumbhare, Mumbai (IN); Vimal Kumar Jain, Mumbai (IN); Kavirayani Indira Priyadarsini, Mumbai (IN)**

(73) Assignee: **Secretary, Department of Atomic Energy, Mumbai (IN)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **17/003,420**

(22) Filed: **Aug. 26, 2020**

(51) **Int. Cl.**
A61K 31/194 (2006.01)
A61P 35/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 31/194** (2013.01); **A61P 35/00** (2018.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,556,451 A 6/1951 Smith
2,729,676 A 1/1956 MacPeck

FOREIGN PATENT DOCUMENTS

KR 101690179 B1 12/2016
WO 2016204561 A1 12/2016

OTHER PUBLICATIONS

Cao et al., *Oncotarget* (2014), 5(17), pp. 7431-7445.*
Carroll et al., "Interaction kinetics of selenium-containing compounds with oxidants", *Free Radical Biology and Medicine*, 2020, pp. 58-68, vol. 155.
Gandhi et al., "Oral administration of 3,3-diselenodipropionic acid prevents thoracic radiation induced pneumonitis in mice by suppressing NF-KB/IL-17/G-CSF/neutrophil axis", *Free Radical Biology and Medicine*, 2019, vol. 145, pp. 3-19.
Gao et al., "A Spherical Nucleic Acid Probe Based on Au—Se Bond", *Analytical Chemistry*, 2020, pp. 8459-8463, vol. 92, No. 12.
Gota et al., "Biodistribution and Pharmacokinetic Study of 3,3'-Diseleno Dipropionic Acid (DSePA), A Synthetic Radioprotector, in Mice", *European Journal of Drug Metabolism and Pharmacokinetics*, 2015, pp. 839-844, vol. 41, No. 6.
Kunwar et al., "3,3'-Diselenodipropionic Acid, an Efficient Peroxyl Radical Scavenger and a GPx Mimic, Protects Erythrocytes (RBCs) from AAPH-Induced Hemolysis", *Chemical Research in Toxicology*, 2007, pp. 1482-1487, vol. 20, No. 10.
Kunwar et al., "In vivo radioprotection studies of 3,3'-diselenodipropionic acid, a selenocysteine derivative", *Free Radical Biology & Medicine*, 2010, pp. 399-410, vol. 48, No. 3.
Kunwar et al., "Anti-apoptotic, anti-inflammatory, and immunomodulatory activities of 3,3'-diselenodipropionic acid in mice exposed to whole body γ -radiation". *Archives of Toxicology*, 2011, pp. 1395-1405, vol. 85, No. 11.
Kunwar et al., "A Selenocysteine Derivative Therapy Affects Radiation-Induced Pneumonitis in the Mouse", *American Journal of Respiratory Cell and Molecular Biology*, 2013, pp. 654-661, vol. 49, No. 4.
Kunwar et al., "Toxicological safety evaluation of 3,3'-diselenodipropionic acid (DSePA), a pharmacologically important derivative of selenocysteine", *Regulatory Toxicology and Pharmacology*, 2018, pp. 159-167, vol. 99.
Singh et al., "In silico investigation on the binding of organoselenium compounds with target proteins of SARS-CoV-2 infection cycle", *ChemRxiv*, 2020, 31 pages, retrieved from <https://doi.org/10.26434/chemrxiv.12594134.v1>.

* cited by examiner

Primary Examiner — Brian J Davis

(74) *Attorney, Agent, or Firm* — The Webb Law Firm

(57) **ABSTRACT**

The present invention describes the method of using a synthetic organoselenium compound, DSePA for management of non-small cell lung carcinoma (NSCLC) and chronic myelogenous leukemia (CML). The method comprises administering DSePA orally at a dosage of 1 mg/Kg body weight daily for inhibiting the growth of A549 (representative of NSCLC) and K562 (representative of CML) tumor in mice models. Additionally, the said compound also inhibits the proliferation of other cancer cells of NSCLC (HOP-62 and H460), breast (MDA-MB-231), white blood cells (JURKAT and U-937), oral (SCC-40), colon (HT-29), kidney (A498) and cervix (SiHA) origins in cellular models at a much lower concentration than that needed to inhibit the growth of normal cells.

14 Claims, 5 Drawing Sheets